Anthony J. Gringeri
Nessuna posizione attualmente
Storia della carriera di Anthony J. Gringeri
Precedenti posizioni note di Anthony J. Gringeri
Società | Posizione | Inizio | Fine |
---|---|---|---|
EOM PHARMACEUTICALS HOLDINGS, INC. | Direttore/Membro del Consiglio | 13/12/2016 | 15/10/2018 |
Amministratore Delegato | 13/12/2016 | 15/10/2018 | |
Corporate Officer/Principal | 28/08/2013 | 13/12/2016 | |
Presidente | 13/12/2016 | 15/10/2018 | |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 16/05/2011 | 01/01/2012 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Direttore operativo | 01/01/2006 | 02/12/2009 |
Formazione di Anthony J. Gringeri
The State University of New York | Doctorate Degree |
Rochester Christian University | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Paesi Bassi | 2 |
Posizioni
Doctorate Degree | 2 |
Corporate Officer/Principal | 2 |
Chief Operating Officer | 1 |
Settori
Health Technology | 3 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 3 |
---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
ImmunoCellular Therapeutics Ltd.
ImmunoCellular Therapeutics Ltd. BiotechnologyHealth Technology ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ. | Health Technology |
- Borsa valori
- Insiders
- Anthony J. Gringeri
- Esperienza